programmed cell death protein 1 (PD-1) inhibitor carrelizumab and Rivoceranib in combination (hereinafter referred to as "Double Ai" combination) received a Complete Response Letter (CRL) from the FDA.

On April 23, global biopharmaceutical company Incyte announced the finalization of an agreement to fully acquire clinical-stage drug development company Escient Pharmaceuticals.

This acquisition will not only enrich Novartis's research and development pipeline in Radioligand Therapy (RLT) but will also enhance the company’s research foundation and clinical supply capabilities in oncology and RLT platform innovations.

The disclosed CS5001 is an ADC targeting ROR1, featuring a unique design.

CMG901 (AZD0901) is a potentially first-in-class antibody-drug conjugate targeting Claudin 18.2, conjugated with monomethyl auristatin E (MMAE) as the payload.

At the upcoming ASCO conference, Mabwell (Shanghai) Bioscience will present the Phase I/II clinical study results of 9MW2821 for several advanced solid tumors through an oral report.

JSKN003 is a novel ADC targeting two distinct epitopes of HER2, independently developed by Alphamab Biopharmaceuticals utilizing its proprietary glycan-based site-specific conjugation platform.

Medilink Therapeutics will present preliminary results from the first human clinical Phase 1 trial of YL202 for the treatment of locally advanced or metastatic non-small cell lung cancer and breast cancer (NCT05653752).

RemeGen Showcases 16 New Clinical Studies on ADCs Disitamab Vedotin and RC88 Targeting Multiple Cancer Types at Conference.

Lepu Biopharma is an innovative biopharmaceutical company focused on the field of oncology treatment, particularly in targeted therapy and immunotherapy.

At the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Kelun Botai Biomedicine will disclose the research progress of SKB264.

Innovent Biologics will present a poster demonstrating the safety and efficacy of IBI343 in patients with advanced pancreatic ductal adenocarcinoma or cholangiocarcinoma.